EUVIMED · CrossrefZeitschrift
Journal of Hematology & Oncology
ISSN 1756-8722 · Springer Science and Business Media LLC
Neueste Artikel
A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1
PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Plonmarlimab, a GM-CSF-neutralizing antibody, for macrophage activation syndrome
Global cancer statistics among older adults in 2024 with projections to 2050: a multi-source population-based analysis
T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis
Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives
Glutathione reductase deficiency potentiates the immunogenicity of ferroptosis and cuproptosis via amplified reactive oxygen species accumulation and cGAS-STING pathway activation
High-definition spatial transcriptomics visualizes the cellular and molecular architecture underlying perineural invasion in localized prostate cancer
Current and future therapies for triple-negative breast cancer
Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
Tumor microenvironment–specific nanomedicine: from biology-driven to multi-omics–guided precision engineering
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases
Cytokines and cancer-associated fibroblasts
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial
Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors
CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AML
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance
BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial
A subcellular spatial atlas illuminates the microenvironmental remodeling of perineural invasion in distal cholangiocarcinoma
Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy
EUVIMED